PARP inhibitor

src: i.ytimg.com

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

In addition to their use in cancer therapy, PARP inhibitors are considered a potential treatment for acute life-threatening diseases, such as stroke and myocardial infarction, as well as for long-term neurodegenerative diseases.

Video PARP inhibitor

Mechanism of action

DNA is damaged thousands of times during each cell cycle, and that damage must be repaired, including in cancer cells. Otherwise the cells may die due to this damage.

BRCA1, BRCA2 and PALB2 are proteins that are important for the repair of double-strand DNA breaks by the error-free homologous recombinational repair, or HRR, pathway. When the gene for either protein is mutated, the change can lead to errors in DNA repair that can eventually cause breast cancer. When subjected to enough damage at one time, the altered gene can cause the death of the cells.

PARP1 is a protein that is important for repairing single-strand breaks ('nicks' in the DNA). If such nicks persist unrepaired until DNA is replicated (which must precede cell division), then the replication itself can cause double strand breaks to form.

Drugs that inhibit PARP1 cause multiple double strand breaks to form in this way, and in tumours with BRCA1, BRCA2 or PALB2 mutations, these double strand breaks cannot be efficiently repaired, leading to the death of the cells. Normal cells that don't replicate their DNA as often as cancer cells, and that lack any mutated BRCA1 or BRCA2 still have homologous repair operating, which allows them to survive the inhibition of PARP.

Some cancer cells that lack the tumor suppressor PTEN may be sensitive to PARP inhibitors because of downregulation of Rad51, a critical homologous recombination component, although other data suggest PTEN may not regulate Rad51. Hence PARP inhibitors may be effective against many PTEN-defective tumours (e.g. some aggressive prostate cancers).

Cancer cells that are low in oxygen (e.g. in fast growing tumors) are sensitive to PARP inhibitors.

Additional mode of action for PARP inhibitors

2012: Researchers at the National Cancer Institute have discovered a significant new mechanism of action for PARP inhibitors. They have also identified differences in the toxic capabilities of three drugs in this class (niraparib, olaparib, and veliparib), which are currently being tested in clinical trials. Prior to this study, PARP inhibitors were thought to work primarily by blocking PARP enzyme activity, thus preventing the repair of DNA damage and ultimately causing cell death. In this study, scientists established that PARP inhibitors have an additional mode of action: localizing PARP proteins at sites of DNA damage, which has relevance to their anti-tumor activity. The trapped PARP protein-DNA complexes are highly toxic to cells because they block DNA replication. When the researchers tested three PARP inhibitors for their differential ability to trap PARP proteins on damaged DNA, they found that the trapping potency of the inhibitors varied widely, with olaparib being the most potent inhibitor, but MK-4827 the most toxic, and complexes with veliparib the least tightly bound to DNA.

The PARP family of proteins in humans includes PARP1 and PARP2, which are DNA binding and repair proteins. When activated by DNA damage, these proteins recruit other proteins that do the actual work of repairing DNA. Under normal conditions, PARP1 and PARP2 are released from DNA once the repair process is underway. However, as this study shows, when they are bound to PARP inhibitors, PARP1 and PARP2 become trapped on DNA. The researchers showed that trapped PARP-DNA complexes are more toxic to cells than the unrepaired single-strand DNA breaks that accumulate in the absence of PARP activity, indicating that PARP inhibitors act as PARP poisons. These findings suggest that there may be two classes of PARP inhibitors, catalytic inhibitors that act mainly to inhibit PARP enzyme activity and do not trap PARP proteins on DNA, and dual inhibitors that both block PARP enzyme activity and act as PARP poison.

Maps PARP inhibitor

Approved for marketing

• Olaparib (AZD-2281, Lynparza® by Astra Zeneca): In December, 2014, the EMA and US FDA approved olaparib as monotherapy (at 400 mg taken twice per day) for patients with germline BRCA mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
• Rucaparib (PF-01367338, Rubraca® by Clovis Oncology): On December 19, 2016 the US FDA granted accelerated approval for previously treated BRCA-mutant ovarian cancer.In April 2018 it was granted FDA approval.
• Niraparib (MK-4827, Zejula® by Tesaro): In March 2017 approved by US FDA for epithelial ovarian, fallopian tube, and primary peritoneal cancer.. Inhibitor of PARP1 and PARP2.

src: stm.sciencemag.org

Examples in clinical trials

Started Phase III:

• Talazoparib (BMN-673, originally developed by BioMarin Pharmaceutical Inc., currently in development by Pfizer) after trials for advanced hematological malignancies and for advanced or recurrent solid tumors. it started in 2013 a phase III for metastatic germline BRCA mutated breast cancer.
• Veliparib (ABT-888, developed by AbbVie) June 2014 in phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC).

Started Phase II:

• Olaparib (AZD-2281) for breast, ovarian and colorectal cancer. AZ
• Olaparib TOPARP-A trial for use in advanced prostate cancer (published c. April 21, 2015).
• Rucaparib (PF-01367338, AG014699) for metastatic breast and ovarian cancer.
• Veliparib (ABT-888) for metastatic melanoma.
• CEP 9722 for non-small-cell lung cancer (NSCLC)
• E7016 (developed by Eisai): underwent phase II trial in melanoma.

Started Phase I:

• BGB-290 1st dosing July 2014.

Currently Discontinued:

• Iniparib (BSI 201, developed by Sanofi) was determined in 2012 not to be a true PARP inhibitor and failed trial for triple negative breast cancer. In 2013 Sanofi disclosed that iniparib failed to help squamous cell lung cancer patients in a phase III trial, prompting the company to end research into the once-promising compound.

Experimental:

• 3-aminobenzamide, a prototypical PARP inhibitor

src: www.onclive.com

Combination with radiotherapy

The main function of radiotherapy is to produce DNA strand breaks, causing severe DNA damage and leading to cell death. Radiotherapy has the potential to kill 100% of any targeted cells, but the dose required to do so would cause unacceptable side effects to healthy tissue. Radiotherapy therefore can only be given up to a certain level of radiation exposure. Combining radiation therapy with PARP inhibitors offers promise, since the inhibitors would lead to formation of double strand breaks from the single-strand breaks generated by the radiotherapy in tumor tissue with BRCA1/BRCA2 mutations. This combination could therefore lead to either more powerful therapy with the same radiation dose or similarly powerful therapy with a lower radiation dose.

src: mcr.aacrjournals.org

See also

• PARP1
• Parthanatos

src: www.pnas.org

References

src: www.pnas.org

External links

• Parp Inhibitors information site
• PARP structure

Source of article : Wikipedia